Investigators reported on how ctDNA, measured using Natera's patient-specific Signatera assays, corresponded to a patient's disease progression and other biomarkers.
Researchers published the most comprehensive data to date showing that Grail's screening approach can detect and distinguish a significant number of cancers.
The company began offering testing to clinicians in the first quarter of this year and expects volume to grow significantly over the next several months.
A four-year, $5.5 million program will assess whether circulating cell-free DNA testing can improve diagnosis and outcomes for a type of EBV-associated cancer.
Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.
The partners will extend the lung cancer biomarker study to countries in and outside Europe, and see if liquid biopsy could offer benefits to tissue-based testing.
